543 related articles for article (PubMed ID: 18065810)
1. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement.
Iatrou C; Zerbala S; Revela I; Spanou E; Marinaki S; Nakopoulou L; Boletis J
Clin Nephrol; 2009 Jul; 72(1):31-7. PubMed ID: 19640385
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Jones RB; Hiemstra TF; Ballarin J; Blockmans DE; Brogan P; Bruchfeld A; Cid MC; Dahlsveen K; de Zoysa J; Espigol-Frigolé G; Lanyon P; Peh CA; Tesar V; Vaglio A; Walsh M; Walsh D; Walters G; Harper L; Jayne D;
Ann Rheum Dis; 2019 Mar; 78(3):399-405. PubMed ID: 30612116
[TBL] [Abstract][Full Text] [Related]
4. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis.
Joy MS; Hogan SL; Jennette JC; Falk RJ; Nachman PH
Nephrol Dial Transplant; 2005 Dec; 20(12):2725-32. PubMed ID: 16188901
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial.
Silva F; Specks U; Kalra S; Hogan MC; Leung N; Sethi S; Fervenza FC
Clin J Am Soc Nephrol; 2010 Mar; 5(3):445-53. PubMed ID: 20093349
[TBL] [Abstract][Full Text] [Related]
7. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide.
Stassen PM; Tervaert JW; Stegeman CA
Ann Rheum Dis; 2007 Jun; 66(6):798-802. PubMed ID: 17179175
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis.
Koukoulaki M; Jayne DR
Nephron Clin Pract; 2006; 102(3-4):c100-7. PubMed ID: 16286784
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil.
Waiser J; Budde K; Braasch E; Neumayer HH
Am J Kidney Dis; 1999 Sep; 34(3):e9. PubMed ID: 10471756
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing patient survival and renal function outcome in pulmonary-renal syndrome associated with ANCA (+) vasculitis: a single-center experience.
Stangou M; Asimaki A; Bamichas G; Christidou F; Zoumbaridis N; Natse T; Galanis N; Christaki P; Patakas D; Sombolos K
J Nephrol; 2005; 18(1):35-44. PubMed ID: 15772921
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
Kuzuya K; Morita T; Kumanogoh A
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
[TBL] [Abstract][Full Text] [Related]
13. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
Wang J; Hu W; Xie H; Zhang H; Chen H; Zeng C; Liu Z; Li L
Lupus; 2007; 16(9):707-12. PubMed ID: 17728363
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity.
Ibernon M; Poveda R; Vidaller A; Bestard O; Grinyó JM
Clin Nephrol; 2008 Jun; 69(6):395-401. PubMed ID: 18538114
[TBL] [Abstract][Full Text] [Related]
15. Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital.
Draibe J; Poveda R; Fulladosa X; Vidaller A; Zulberti C; Gomà M; Pujol R; Ripoll È; Torras J; Grinyó JM
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1():i132-7. PubMed ID: 25805744
[TBL] [Abstract][Full Text] [Related]
16. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis.
Tang Z; Yang G; Yu C; Yu Y; Wang J; Hu W; Zeng C; Chen H; Liu Z; Li L
Nephrology (Carlton); 2008 Dec; 13(8):702-7. PubMed ID: 18771470
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
[TBL] [Abstract][Full Text] [Related]
18. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil in low doses stabilizes and improves antineutrophil cytoplasmic antibody-associated vasculitis and lupus nephritis.
Kazderova M; Jancova E; Rysava R; Merta M; Tesar V
Arch Med Res; 2008 Jan; 39(1):115-9. PubMed ID: 18068004
[TBL] [Abstract][Full Text] [Related]
20. Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis.
Haubitz M; de Groot K
Clin Nephrol; 2002 Jun; 57(6):421-4. PubMed ID: 12078944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
